|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
EP2055189A1
(en)
|
2003-04-09 |
2009-05-06 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
WO2006127896A2
(en)
|
2005-05-25 |
2006-11-30 |
Neose Technologies, Inc. |
Glycopegylated factor ix
|
|
US8791070B2
(en)
|
2003-04-09 |
2014-07-29 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US9005625B2
(en)
|
2003-07-25 |
2015-04-14 |
Novo Nordisk A/S |
Antibody toxin conjugates
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
|
WO2005055930A2
(en)
*
|
2003-12-03 |
2005-06-23 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
|
CN101072789B
(zh)
|
2004-01-08 |
2013-05-15 |
生物种属学股份公司 |
肽的o-连接的糖基化
|
|
EP1771066A2
(en)
|
2004-07-13 |
2007-04-11 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
|
|
ES2566670T3
(es)
|
2004-10-29 |
2016-04-14 |
Ratiopharm Gmbh |
Remodelación y glucopegilación del factor de crecimiento de fibroblastos (FGF)
|
|
MX2007008229A
(es)
|
2005-01-10 |
2007-09-11 |
Neose Technologies Inc |
Factor estimulador de colonias de granulocitos glicopegilado.
|
|
EP2386571B1
(en)
|
2005-04-08 |
2016-06-01 |
ratiopharm GmbH |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
WO2006108590A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation factor viii with enhanced stability and its derivates
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
WO2007065691A2
(en)
|
2005-12-07 |
2007-06-14 |
Technische Universität München |
Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
|
|
US20090203077A1
(en)
*
|
2006-06-30 |
2009-08-13 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
EP2520586A1
(en)
*
|
2006-06-30 |
2012-11-07 |
The Regents of the University of Michigan |
Method of producing factor VIII proteins by recombinant methods
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
PT2126106T
(pt)
|
2007-02-23 |
2017-12-12 |
Sk Chemicals Co Ltd |
Proceso para produzir e purificar o fator viii e seus derivados
|
|
EA017770B1
(ru)
|
2007-04-03 |
2013-03-29 |
Биодженерикс Аг |
Способы лечения с использованием гликопэгилированного g-csf
|
|
CN101778859B
(zh)
|
2007-06-12 |
2014-03-26 |
诺和诺德公司 |
改良的用于生产核苷酸糖的方法
|
|
CN104152489A
(zh)
|
2007-11-01 |
2014-11-19 |
罗切斯特大学 |
具有增加的稳定性的重组因子viii
|
|
CA2711503A1
(en)
*
|
2008-01-08 |
2009-07-16 |
Biogenerix Ag |
Glycoconjugation of polypeptides using oligosaccharyltransferases
|
|
EP2626080A3
(en)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjugated factor VIII molecules
|
|
CN104045716A
(zh)
*
|
2008-05-16 |
2014-09-17 |
拜耳医药保健有限公司 |
靶向性凝固因子及其使用方法
|
|
JP5843357B2
(ja)
|
2009-02-03 |
2016-01-13 |
アムニクス オペレーティング インコーポレイテッド |
延長組換えポリペプチドおよび延長組換えポリペプチドを含む組成物
|
|
JP2013502458A
(ja)
|
2009-08-24 |
2013-01-24 |
アムニクス オペレーティング インコーポレイテッド |
凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法
|
|
WO2011041770A1
(en)
|
2009-10-02 |
2011-04-07 |
The Children's Hospital Of Philadelphia |
Compositions and methods for enhancing coagulation factor viii function
|
|
KR101770849B1
(ko)
|
2009-12-06 |
2017-09-05 |
바이오버라티브 테라퓨틱스 인크. |
인자 ＦⅧ-Ｆｃ의 키메라 및 하이브리드 폴리펩티드, 및 그의 사용방법
|
|
WO2012006623A1
(en)
|
2010-07-09 |
2012-01-12 |
Biogen Idec Hemophilia Inc. |
Systems for factor viii processing and methods thereof
|
|
EA201291482A1
(ru)
|
2010-07-09 |
2013-10-30 |
Байоджен Айдек Хемофилия Инк. |
Химерные факторы коагуляции
|
|
JP5922141B2
(ja)
|
2010-11-05 |
2016-05-24 |
バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ |
増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
|
|
EP3527218A1
(en)
|
2011-06-10 |
2019-08-21 |
Bioverativ Therapeutics Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
HRP20190535T1
(hr)
|
2011-07-08 |
2019-05-17 |
Bioverativ Therapeutics Inc. |
Kimerni i hibridni polipeptidi faktora viii i postupci njihove upotrebe
|
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
|
DK2768522T3
(en)
|
2011-10-18 |
2016-11-14 |
Csl Behring Gmbh |
The use of sulfated glycosaminoglycan for improving the bioavailability of blood coagulation factors.
|
|
EP2768521B1
(en)
|
2011-10-18 |
2016-07-13 |
CSL Behring GmbH |
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
|
|
EP2768853A1
(en)
|
2011-10-18 |
2014-08-27 |
CSL Limited |
Method for improving the stability of purified factor viii after reconstitution
|
|
KR102212098B1
(ko)
|
2012-01-12 |
2021-02-03 |
바이오버라티브 테라퓨틱스 인크. |
키메라 인자 viii 폴리펩티드들과 이의 용도
|
|
EA029560B1
(ru)
|
2012-01-12 |
2018-04-30 |
Байоджен Эмэй Инк. |
Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта
|
|
JP6383666B2
(ja)
|
2012-02-15 |
2018-08-29 |
バイオベラティブ セラピューティクス インコーポレイテッド |
組換え第ｖｉｉｉ因子タンパク質
|
|
MX369862B
(es)
|
2012-02-15 |
2019-11-25 |
Bioverativ Therapeutics Inc |
Composiciones del factor viii y metodos para hacerlas y usarlas.
|
|
EP4079316A1
(en)
|
2012-06-08 |
2022-10-26 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
|
JP2015525222A
(ja)
|
2012-06-08 |
2015-09-03 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
キメラ性凝固因子
|
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
|
KR101395736B1
(ko)
*
|
2012-07-10 |
2014-05-16 |
아주대학교산학협력단 |
인간 혈액응고인자 ⅷ 도메인 특이적 항체 및 이의 제조방법
|
|
EA201792485A3
(ru)
|
2012-07-11 |
2019-03-29 |
Амуникс Оперэйтинг Инк. |
Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты)
|
|
EP3970738A1
(en)
|
2012-07-25 |
2022-03-23 |
Bioverativ Therapeutics Inc. |
Blood factor monitoring assay and uses thereof
|
|
AU2013331000B2
(en)
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP3943102A1
(en)
|
2012-10-30 |
2022-01-26 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
|
PL2956477T5
(pl)
|
2013-02-15 |
2024-05-27 |
Bioverativ Therapeutics Inc. |
Zoptymalizowany gen czynnika viii
|
|
AU2014228506A1
(en)
|
2013-03-15 |
2015-08-13 |
Bioverativ Therapeutics Inc. |
Factor VIII polypeptide formulations
|
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
DK2796145T3
(da)
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
|
US20160251408A1
(en)
|
2013-06-28 |
2016-09-01 |
Biogen Ma Inc. |
Thrombin cleavable linker with xten and its uses thereof
|
|
EP3875106A1
(en)
|
2013-08-08 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
|
TWI667255B
(zh)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
|
EP4332839A3
(en)
|
2013-12-06 |
2024-06-05 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
MY204756A
(en)
|
2014-01-10 |
2024-09-11 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
|
CA2934705C
(en)
*
|
2014-01-20 |
2020-03-31 |
Octapharma Ag |
A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
|
|
JP6609561B2
(ja)
|
2014-02-04 |
2019-11-20 |
バイオジェン・エムエイ・インコーポレイテッド |
翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
MX379126B
(es)
|
2014-08-04 |
2025-03-10 |
Csl Ltd |
Formulación de factor viii.
|
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
|
ES2772933T3
(es)
|
2015-03-06 |
2020-07-08 |
CSL Behring Lengnau AG |
Factor de von Willebrand modificado que tiene una semivida mejorada
|
|
SG10201910896UA
(en)
|
2015-05-22 |
2020-01-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
US10772936B2
(en)
|
2015-05-22 |
2020-09-15 |
CSL Behring Lengnau AG |
Methods for preparing modified von Willebrand factor
|
|
IL257231B
(en)
|
2015-08-03 |
2022-09-01 |
Bioverativ Therapeutics Inc |
Factor ix fusion proteins and methods of making and using same
|
|
WO2017050820A1
(en)
*
|
2015-09-22 |
2017-03-30 |
Novo Nordisk A/S |
Fviii fusion proteins
|
|
EA202190827A1
(ru)
|
2015-11-13 |
2021-11-30 |
Баксалта Инкорпорейтед |
Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
|
|
TWI850587B
(zh)
|
2015-11-13 |
2024-08-01 |
日商武田藥品工業股份有限公司 |
用於ａ型血友病基因治療之編碼表現增加之重組ｆｖｉｉｉ變異體之病毒載體
|
|
ES2909573T3
(es)
|
2016-01-07 |
2022-05-09 |
CSL Behring Lengnau AG |
Factor de von Willebrand truncado mutado
|
|
RS63548B1
(sr)
|
2016-02-01 |
2022-09-30 |
Bioverativ Therapeutics Inc |
Optimizovani geni faktora viii
|
|
WO2017222330A1
(ko)
|
2016-06-24 |
2017-12-28 |
재단법인 목암생명과학연구소 |
재조합 단쇄 fviii 및 그 화학 접합물
|
|
WO2017222337A1
(ko)
|
2016-06-24 |
2017-12-28 |
재단법인 목암생명과학연구소 |
Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
|
|
JP6351679B2
(ja)
*
|
2016-09-30 |
2018-07-04 |
エスケー ケミカルズ カンパニー リミテッド |
第ｖｉｉｉ因子とその誘導体の製造及び精製方法
|
|
SG11201903950UA
(en)
|
2016-11-11 |
2019-05-30 |
CSL Behring Lengnau AG |
Truncated von willebrand factor polypeptides for treating hemophilia
|
|
DK3538134T3
(da)
|
2016-11-11 |
2022-02-07 |
CSL Behring Lengnau AG |
Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
|
|
CA3044838A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
CN110520150A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
使用嵌合凝血因子治疗血友病性关节病的方法
|
|
US11141466B2
(en)
|
2017-06-22 |
2021-10-12 |
CSL Behring Lengnau AG |
Modulation of FVIII immunogenicity by truncated VWF
|
|
KR20250040746A
(ko)
|
2017-08-09 |
2025-03-24 |
바이오버라티브 테라퓨틱스 인크. |
핵산 분자 및 이의 용도
|
|
CN111295094A
(zh)
|
2017-10-09 |
2020-06-16 |
泰尔茂比司特生物技术有限公司 |
冻干容器及使用冻干容器的方法
|
|
CN111918674A
(zh)
|
2018-02-01 |
2020-11-10 |
比奥维拉迪维治疗股份有限公司 |
表达因子viii的慢病毒载体的用途
|
|
CN112203646A
(zh)
|
2018-04-04 |
2021-01-08 |
西吉隆医疗股份有限公司 |
可植入颗粒和相关方法
|
|
LT3793588T
(lt)
|
2018-05-18 |
2025-06-25 |
Bioverativ Therapeutics Inc. |
Hemofilijos a gydymo būdai
|
|
CA3106590A1
(en)
|
2018-07-16 |
2020-01-23 |
Baxalta Incorporated |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
EP3852780A1
(en)
*
|
2018-09-19 |
2021-07-28 |
Cell Machines, Inc. |
Methods and compositions related to improved factor viii long half-life coagulation complexes
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
TWI851647B
(zh)
|
2019-01-16 |
2024-08-11 |
日商武田藥品工業股份有限公司 |
用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
|
|
CA3129532A1
(en)
|
2019-02-15 |
2020-08-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
|
WO2020242552A1
(en)
|
2019-03-14 |
2020-12-03 |
Terumo Bct Biotechnologies, Llc |
Multi-part lyophilization container and method of use
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
KR20220022110A
(ko)
*
|
2019-06-05 |
2022-02-24 |
크리스퍼 테라퓨틱스 아게 |
개선된 인자 viii 발현을 사용한, a형 혈우병을 위한 유전자 편집
|
|
TW202115127A
(zh)
|
2019-06-19 |
2021-04-16 |
美商百歐維拉提夫治療公司 |
治療血友病及低骨質密度之方法及組成物
|
|
US20220389082A1
(en)
|
2019-07-04 |
2022-12-08 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
|
|
US12403164B2
(en)
|
2019-09-30 |
2025-09-02 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
JP7680442B2
(ja)
|
2019-11-11 |
2025-05-20 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド
|
|
EP4073106A2
(en)
|
2019-12-12 |
2022-10-19 |
Takeda Pharmaceutical Company Limited |
Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
|
|
JP7681268B2
(ja)
*
|
2020-03-30 |
2025-05-22 |
シスメックス株式会社 |
血液凝固活性の測定方法
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
CN117858895A
(zh)
|
2021-06-14 |
2024-04-09 |
武田药品工业株式会社 |
使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
|
|
TW202323274A
(zh)
|
2021-08-23 |
2023-06-16 |
美商百歐維拉提夫治療公司 |
優化因子viii基因
|
|
AU2022355088A1
(en)
|
2021-09-30 |
2024-05-16 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
JP2025534659A
(ja)
|
2022-10-11 |
2025-10-17 |
シギロン セラピューティクス， インコーポレイテッド |
疾患治療のための改変細胞及び移植可能エレメント
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|